Published in Am J Transl Res on July 15, 2016
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med (2006) 5.61
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
Chordoma: current concepts, management, and future directions. Lancet Oncol (2012) 2.63
Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer (2000) 2.40
Operative management of sacral chordoma. J Bone Joint Surg Am (2005) 2.12
Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol (2003) 2.12
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother (2006) 1.81
Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery (1999) 1.79
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res (2008) 1.58
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2014) 1.53
Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J Bone Joint Surg Am (1993) 1.52
Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol (1996) 1.50
PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45
Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) (1999) 1.45
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44
PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One (2013) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
The surgical management of sacrococcygeal chordoma. Cancer (1999) 1.36
Clinical and pathologic review of 48 cases of chordoma. Cancer (1985) 1.30
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol (2008) 1.25
Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One (2011) 1.24
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol (2015) 1.21
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis (2015) 1.15
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) (2015) 1.14
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol (2015) 1.11
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol (2014) 1.03
Novel therapeutic targets in chordoma. Expert Opin Ther Targets (2012) 1.02
A review of the surgical management of sacral chordoma. Eur J Surg Oncol (2014) 1.01
Chordoma: natural history and treatment results in 33 cases. J Surg Oncol (1988) 0.99
Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology (2014) 0.99
Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol (2005) 0.98
Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center. Neuro Oncol (2014) 0.97
Surgical management of primary bone tumors of the spine: validation of an approach to enhance cure and reduce local recurrence. Spine (Phila Pa 1976) (2011) 0.95
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget (2015) 0.94
Chordoma: an analysis of twenty cases treated over a twenty-year span. J Surg Oncol (1975) 0.92
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol (2015) 0.89
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol (2014) 0.87
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget (2015) 0.86
Fifty years of experience with chordomas in southeast Scotland. Neurosurgery (1985) 0.86
PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepatogastroenterology (2013) 0.86
Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma. J Neurooncol (2013) 0.85
Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients. Eur Spine J (2015) 0.85
Prognostic Factors in the Operative Management of Sacral Chordomas. World Neurosurg (2015) 0.85
Prognostic factors in spinal chordoma: A systematic review. Clin Neurol Neurosurg (2015) 0.81
MicroRNA-155 expression is independently predictive of outcome in chordoma. Oncotarget (2015) 0.80
Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Int J Clin Exp Pathol (2015) 0.77